March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
March 2026 in “Dermatology and Therapy” More severe alopecia areata can lower quality of life.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata cases in children are rising, especially in females and low-income regions, with a projected increase in China and decrease in the USA.
December 2025 in “ADMET & DMPK” Personalized treatments for hair loss focus on specific genetic and biological pathways.
November 2025 in “International Journal of Research in Medical Sciences” Diffuse alopecia in females is often linked to certain medications, diseases, and low hemoglobin, while female pattern hair loss is linked to age, duration, and family history.
November 2025 in “Frontiers in Medicine” Baseline severity and relapse history affect alopecia areata treatment and recurrence.
November 2025 in “Frontiers in Medicine” The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
Combining psychodermatology and PRP therapy can improve skin condition treatment by addressing both mental and physical health.
October 2025 in “Progress In Microbes & Molecular Biology” PCOS is linked to gut bacteria changes, suggesting gut-focused treatments might help.
October 2025 in “Clinical Cosmetic and Investigational Dermatology” Targeting specific cell interactions may help treat skin fibrosis.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
June 2025 in “Reports of Vinnytsia National Medical University” Men with alopecia areata tend to have larger limb and trunk circumferences than healthy men.
April 2025 in “Tạp chí Y Dược học Cần Thơ” Hair loss and mental health issues like anxiety and insomnia affect each other, impacting quality of life.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
Resident doctors had more facial skin discoloration than medical students during COVID-19.
Technology can improve sexual dysfunction in chronic disease patients but faces challenges like cost and accessibility.
January 2025 in “RSC Pharmaceutics” Smart microneedles using advanced tech could improve psoriasis treatment.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “Journal of Rawalpindi Medical College” Alopecia Areata affects both genders almost equally, mostly on the scalp, with common signs like yellow dots and exclamation mark hairs, especially in young people.
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata might help slow down certain cancers.
August 2024 in “Bioscience of Microbiota Food and Health” Microbes might play a role in vitiligo.
May 2024 in “Journal of Education, Health and Sport” Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
February 2024 in “International neuropsychiatric disease journal” Alopecia areata severely impacts quality of life, mental health, and work productivity.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.